SHR-1703
As of the edition of 20 October 2026, SHR-1703 is a drug known only by a code name: in active development; acts on IL5.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 7, 1 stopped early
- Disease areas
- Immune system; Lungs and airways; Blood and lymph; Heart and blood vessels; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of SHR-1703.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL5 | Interleukin-5 | P05113 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 1 | 1 | 1 |
| Phase 2 | 2 | 1 | 1 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jiangsu HengRui Medicine | Lead sponsor of trials | 2020 to now |
| Atridia | Lead sponsor of trials | 2021 to now |
| Guangdong Hengrui Pharmaceutical | Lead sponsor of trials | 2023 to now |